Message from the MVI director
Read more »
Personal stories from the field about malaria
Read more »
Image credit: M. Nze Ndong Pascal Romuald, Schweitzer Hospital
Partnering with us
We are pursuing a range of vaccine development approaches with an expanding circle of industry, academic, and government partners.
Our portfolio
We maintain a diverse portfolio of projects, including preclinical feasibility studies, translational projects, and one advanced clinical project.
What we do and how we do it
We provide funding and technical support to partners worldwide to accelerate the development of malaria vaccines. We also work to ensure that malaria vaccines will reach those who need them.
Sustain Gains, Save Lives: Invest in Malaria
Malaria deaths down, but progress fragile, says WHO
Malaria deaths have fallen by more than 25 percent globally since 2000 and by 33 percent in Africa, says the World Malaria Report 2011 of the World Health Organization (WHO). However, projected funding shortfall threatens gains.
MVI collaborates with National Institute of Allergy and Infectious Diseases and Johns Hopkins
Partnership to evaluate potential vaccine candidate designed to prevent malaria transmission from mosquitoes to humans.
Twitter
Flickr